<DOC>
	<DOCNO>NCT02743494</DOCNO>
	<brief_summary>The purpose study determine whether nivolumab improve overall survival , disease-free survival , compare placebo .</brief_summary>
	<brief_title>Study Adjuvant Nivolumab Placebo Subjects With Resected Esophageal Gastroesophageal Junction Cancer</brief_title>
	<detailed_description />
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosed Stage II/III carcinoma esophagus gastroesophageal junction Completed preoperative chemo radiotherapy follow surgery Diagnosed residual pathologic disease surgically render free disease negative margin follow complete resection Diagnosed cervical esophageal carcinoma Diagnosed Stage IV resectable disease Did receive concurrent chemoradiotherapy prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>